eli lilly weight loss drug india
Eli Lilly has launched its weight-loss and type 2 diabetes medication, Mounjaro (tirzepatide), in India following approval from the Central Drugs Standard Control Organisation. This once-weekly injectable drug is available in single-dose vials, with the 2.5 mg vial priced at ₹3,500 and the 5 mg vial at ₹4,375. Mounjaro functions by activating hormone receptors that regulate blood sugar levels and appetite, aiding in weight management. However, potential side effects include gastrointestinal issues, pancreatitis, hypoglycemia, and gallbladder problems. Individuals with specific health conditions should consult a doctor before use. The introduction of Mounjaro is expected to intensify competition in India's obesity treatment market. Novo Nordisk plans to launch its weight-loss drug, Wegovy (semaglutide), by 2026 as its active ingredient is set to go off-patent in India. Additionally, Indian pharmaceutical companies like Sun Pharmaceutical, Biocon, Zydus Lifesciences, C...